BEHBAHANI ALI sold 45.1% of their position (13.68K shares) of CRISPR THERAPEUTICS AG on the open market
Open‑market sale worth $780.9K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/21/2026ACC: 0001193125-26-396944
-13.68K
Net shares
Net seller
$780.9K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
30K acquired · 43.68K disposed
Non-Derivative Transactions2
Common Shares
Direct
Shares
+30K
Price / share
$14.00
Trade value
$420K
% of position
9493.7%
9/17/2026
316.00→30.32K
Common Shares
Direct
Shares
−13.68K
Price / share
$57.09
Trade value
$780.94K
% of position
45.1%
9/17/2026
30.32K→16.64K
Total
Net shares
+16.32K
Net value
-$360.94K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 9/17/2026 | M · Option Exercise | +30K | $14.00 | $420K | 9493.7% | 316.00 | 30.32K |
| Common Shares Direct | 9/17/2026 | S · Sale | −13.68K | $57.09 | $780.94K | 45.1% | 30.32K | 16.64K |
| Total | +16.32K | -$360.94K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Shares
30K shares
Shares
−30K
Strike price
14
Held after
0.00
Exercisable
—
9/17/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Shares30K shares | 9/17/2026 | M · Option Exercise | −30K | 14 | — | 0.00 |
Non-Derivative Holdings (Post-Transaction)1
Common Shares
IndirectShares owned29.00
Total
29.00 indirect29.00
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Shares | 29.00 | Indirect |
| Total | 29.00 | 29.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported